Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	Semaglutide Ozempic Sign up to track	Tirzepatide Mounjaro Sign up to track
Category	Metabolic & Weight Loss	Metabolic & Weight Loss
Key Benefits	•Significant weight loss (average 15-20% body weight) •Improves glycemic control in diabetes •Reduces appetite and food cravings •Cardiovascular benefits +2 more	•Superior weight loss compared to semaglutide (average 20-25%) •Effective diabetes management •Improves insulin sensitivity •Cardiovascular protection +2 more
Dosage	0.25-2.4 mg mg	2.5-15 mg mg
Frequency	Once weekly	Once weekly
Administration	Subcutaneous	Subcutaneous
Mechanism	Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It is FDA-approved for type 2 diabetes management (Ozempic) and chronic weight management (Wegovy). It works by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.	Tirzepatide is a novel dual GIP/GLP-1 receptor agonist. It is the first medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. FDA-approved for type 2 diabetes and weight management.
Side Effects / Risks	Not specified	Not specified
Research Status	FDA-approved for diabetes (Ozempic) and weight management (Wegovy)	FDA-approved for diabetes (Mounjaro) and weight management (Zepbound)